Article

Parents warned about 'medical hoax' surrounding optic nerve hypoplasia

Two pediatric ophthalmologists at St. Louis Children's Hospital, Lawrence Tychsen, MD, and Gregg Lueder, MD, are trying to warn the public about what they call a "21st-century snake oil" scam, according to a prepared statement issued by the hospital.

Key Points

St. Louis-Two pediatric ophthalmologists at St. Louis Children's Hospital, Lawrence Tychsen, MD, and Gregg Lueder, MD, are trying to warn the public about what they call a "21st-century snake oil" scam, according to a prepared statement issued by the hospital.

Recent stories in the media report that parents are taking their children to China for umbilical cord stem cell (CSC) infusions to treat optic nerve hypoplasia (ONH), a disease that causes partial blindness at birth. The treatments, which are paid for entirely out of pocket by the parents, can cost $50,000 or more.

During the procedure, CSCs are extracted from the umbilical cords of Chinese mothers and their newborns, and are then injected into the fluid around the spinal cord of the American children. The parents of the recipients are led to believe by Chinese doctors that the CSCs are an effective treatment.

Aside from ethical concerns, the injections could be dangerous, introducing infectious or toxic matter into the brain fluids, said Dr. Tychsen and Dr. Lueder, who also are professors of ophthalmology and visual sciences at Washington University School of Medicine in St. Louis.

The procedure would not work for several reasons, according to Dr. Tychsen:

Dr. Lueder said that parents of children with ONH should not despair, however. "Many babies born with ONH will have some improvement as they mature, because they learn to exploit more effectively the optic fibers that remain." He added that many children with ONH function reasonably well in school using large print, magnifiers, and other aids designed for people whose vision is impaired.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.